| Melisa June Sigley, PHARMD, CDE | |
|
51 Southland Dr, Fairmont, Fairmont, WV 26554-2244 | |
| (304) 368-9355 | |
| (304) 368-5422 |
| Full Name | Melisa June Sigley |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 51 Southland Dr, Fairmont, West Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407006315 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RP0007046 (West Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Melisa June Sigley, PHARMD, CDE 51 Southland Dr, Fairmont, Fairmont, WV 26554-2244 Ph: (304) 368-9355 | Melisa June Sigley, PHARMD, CDE 51 Southland Dr, Fairmont, Fairmont, WV 26554-2244 Ph: (304) 368-9355 |
News Archive
First it was an apple, now it is an aspirin a day that may keep the doctor away.
The Center for Science in the Public Interest was joined today by victims, consumer advocacy, and public health organizations in urging Congress to support the Food and Drug Administration (FDA) efforts to protect consumers from contaminated oysters that each year cause scores of serious illnesses and deaths. The blood infection caused by Vibrio vulnificus bacteria in oysters is one of the most deadly foodborne illnesses, killing half of the people infected. Those who survive can have painful lesions and fluid-filled blisters all over their bodies, sometimes requiring limbs to be amputated. Four methods of post-harvest processing have proven effective at destroying the bacteria without harming the texture or flavor of the oysters.
Starting June 2013, the Porter Cancer Care Center at Porter Adventist Hospital becomes one of the few facilities in the country to offer highly advanced radiation therapy and radiosurgery cancer treatment options using the new Varian TrueBeam image-guided radiotherapy system.
BioCryst Pharmaceuticals, Inc. announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208) added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.
› Verified 4 days ago
Krista Harrison, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 300 Fairmont Ave, Fairmont, WV 26554 Phone: 304-366-6182 Fax: 304-363-6389 | |
Kandy Anntonette Fitch, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1322 Locust Ave, Fairmont, WV 26554 Phone: 304-366-0700 | |
Ms. Anne E Everly, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1322 Locust Ave, Fairmont, WV 26554 Phone: 304-366-0700 Fax: 304-366-9529 | |
Mark Benedetti, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 32 Tygart Mall Loop, Fairmont, WV 26554 Phone: 304-366-9115 Fax: 304-366-1583 | |
Travis Skinner, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 32 Tygart Mall Loop, Fairmont, WV 26554 Phone: 304-366-9115 | |
Kayla Ledsome, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 177 Middletown Rd Ste 2, Fairmont, WV 26554 Phone: 304-368-9355 | |
Mark Elliott Morris, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1322 Locust Ave, Fairmont, WV 26554 Phone: 304-367-8750 Fax: 304-333-0234 |